Transport Signals and Transcription-dependent Nuclear Localization of the Putative DEAD-box Helicase MDDX28*,

Rut Valgardsdottir {ddagger} and Hans Prydz §

From the Biotechnology Centre of Oslo, University of Oslo, Gaustadalleen 21, N0349 Oslo, Norway

Received for publication, January 27, 2003 , and in revised form, March 18, 2003.
    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The human protein MDDX28 is a putative RNA helicase and a nucleocytoplasmic shuttling protein also localized to the mitochondria. Its localization is novel among RNA helicases. We have studied its intracellular targeting signals and show that the first 20 amino acids of MDDX28 are necessary and sufficient for both mitochondrial import and nuclear export of the protein. Mutation of the five leucines in the sequence to alanines abolished the mitochondrial targeting signal as well as greatly reducing the nuclear export signal, indicating that these signal sequences are highly overlapping. Two short stretches of basic amino acids separated by 44 residues were both necessary and sufficient for full nuclear localization. However, they were not absolutely essential, because the protein was present in 7% of the nuclei when both signals were mutated. This indicates that MDDX28 contains another unidentified weak nuclear localization signal(s). Three basic domains in the N-terminal half of the protein and its RNA binding ability were essential for nucleolar localization as well as transcription-inhibition-dependent localization to nuclear subcompartments. Two of these basic domains were the same as those constituting the nuclear localization signal, suggesting that they are responsible for bringing the protein into the nucleus to the sites of RNA binding. Our results indicate that MDDX28 nucleo-cytoplasmic shuttling is dependent on the availability of nascent RNA.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
MDDX28 (mitochondrial DEAD-box polypeptide 28) is a human putative RNA helicase that contains all the conserved DEAD-box motifs and has around 30% homology with other helicases (1). A mouse protein with 75% homology to MDDX28 has recently been cloned (2), and an incomplete sequence of the rat homologue is available (GenBankTM accession number AC094385 [GenBank] .4). RNA helicases unwind double-stranded RNA using nucleoside triphosphates as a source of energy and serve a wide range of roles in the cell. Recently, RNA helicases have also been suggested to be RNPases that displace proteins from double-stranded RNA substrates and RNA chaperones facilitating correct RNA folding (3, 4). Crystallographic studies of several RNA helicases suggested that the conserved motifs form a large functional domain involved in hydrolyzing nucleoside triphosphate, mainly ATP, and in coupling the hydrolysis to the unwinding process (for a review, see Ref. 5).

MDDX28 was recently shown to contain an RNA-dependent ATP-hydrolyzing activity (1). Endogenous MDDX28 is localized in the mitochondria and the nucleus, where it is also found in the nucleolus. MDDX28-EGFP1 fusion protein has the same localization as the endogenous protein. In addition, and probably like the endogenous MDDX28, it shuttles between the nucleus and the cytoplasm (1). The double localization of MDDX28 is novel among RNA helicases and raises questions about the role of the protein.

All cellular proteins except for 13 mitochondrial proteins are encoded in the nucleus. The nuclear transcripts are transported to the cytoplasm where they are translated into proteins that are transported to their intracellular destinations. Much of the intracellular transport goes through large protein complexes in the intracellular membranes, e.g. of the nucleus and mitochondria, and is largely an active process. The transport involves a localization signal(s) present on the protein itself or on an associated factor and various types of transporter proteins or transporter complexes. Research on localization signals has revealed that there is no simple consensus signal for any of the intracellular compartments, suggesting that different transporter and control mechanisms apply. Several proteins localize to more than one compartment of the cell and, therefore, need to carry multiple transport signals. Proteins that localize to mitochondria and nucleus regulate the localization through formation of different isoforms by alternative splicing or by alternative transcription or translation initiation (6, 7, 8, 9, 10). The Mddx28 gene contains no introns and no internal ATG sites. Therefore, no isoforms can be made of the protein, and its intracellular localization has to be otherwise determined. The aim of the present study was to identify the targeting determinants of MDDX28 as a step toward understanding the function of the protein as well as the control mechanisms for the intracellular localization.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Expression Constructs—The EGFP-N1 vector (Clontech) was used to make the wild type MDDX28-EGFP-N1 construct (1). In total, 36 deletion and mutation constructs were made (see Fig. 1 and Table I). These will be referred to by the missing amino acids (e.g. {Delta}2–139 is missing amino acids 2–139) or by the mutated amino acids (e.g.330GAT -> AAA, having mutated the amino acid sequence GAT at position 330–332 to AAA). Double deletions have been given serial names with two {Delta}sinthe prefix ({Delta}{Delta}1 etc.). All constructs were sequenced on an ALF DNA Sequencer (Amersham Biosciences) to verify successful mutagenesis.



View larger version (34K):
[in this window]
[in a new window]
 
FIG. 1.
Recombinant expression constructs of MDDX28-EGFP-N1 and subcellular localization of the corresponding protein. Open boxes, full-length protein; gray boxes, conserved DEAD-box domains; black boxes, domains with basic amino acids. Deleted regions are indicated with a line. Mutations are indicated with arrowheads. Black boxes at the C terminus of the constructs represent EGFP-N1. The last two constructs show the short variant of TCF11 with insert (black boxes). The mutants are further described in the text. The nuclear localization (N) is described as intense (+++), as in wild type (++), greatly reduced intensity as compared with wild type (+), and no nuclear localization (-). The localization in mitochondria (M), nucleolus (No), cytoplasm (C), and in punctate nuclear structures during treatment with actinomycin D (S) is indicated with a plus (localization) or minus symbol (no localization). "(+)" indicates greatly reduced localization. nd, not determined.

 

View this table:
[in this window]
[in a new window]
 
TABLE I
Recombinant expression constructs of MDDX28 containing mutations in the four basic domains (BS 1-4)

The amino acid sequence in the basic domains is shown except for the fourth domain (BS-4), which is shown either with the wild type sequence or as a deletion ({Delta}). Localization in the nucleus (N) is described as ++ as in wild type, + greatly reduced intensity as compared to wild type. Nucleolar localization (No) is indicated with + (localization) or - (no localization).

 

Two in-frame deletions were made by cleaving the wild type plasmid with XmnI and BclI (to make {Delta}149–274) or with BclI and AgeI (to make {Delta}276–540). The fragments were treated with Klenow and ligated. Five deletions were made by PCR. {Delta}44–540 contained BamHI-digested fragment amplified with forward primer, 5'-GG TGG ATC CTG TAG AGC CAC TGG GAT GC-3', and the wild type reverse primer (1). {Delta}2–20 contained BamHI/EcoRI-digested fragment amplified with forward primer, 5'-GGA ATT CAG CCA CCA TGC GAC GGG GCC-3', and the wild type reverse primer. {Delta}2–139 contained BamHI/EcoRI-digested fragment amplified with forward primer, 5'-GGA ATT CAG CCA CCA TGG CAC TAC AGG AGG CTG C-3', and the wild type reverse primer. {Delta}520–540 contained BamHI-digested fragment amplified with the wild type forward primer and the reverse primer, 5'-GGT GGA TCC CGA GCC GCC AGC TCA ATC TT-3'. {Delta}2–274 contained BamHI/EcoRI-digested fragment amplified with forward primer, 5'-GGA ATT CAG CCA CCA TGA TCA GTC TGG AGC AAC TC-3', and the wild type reverse primer. Double deletions were made by combination of the methods described above. {Delta}{Delta}1 was made by amplification of the wild type plasmid with {Delta}2–139 forward primer and {Delta}520–540 reverse primer. {Delta}{Delta}2 was made by amplification of the {Delta}149–274 plasmid with wild type forward primer and {Delta}520–540 reverse primer. {Delta}{Delta}4 was made with in-frame deletion of {Delta}2–139 as described above for {Delta}276–540. {Delta}{Delta}7 was made with BamHI/EcoRI fragment amplified with {Delta}2–274 forward primer and {Delta}520–540 reverse primer.

Point-mutated constructs were made by site-directed mutagenesis following a protocol from Stratagene using the wild type MDDX28-EGFP-N1 plasmid as template. The 330GAT -> AAA mutation was made with amplification using the primers 5'-CAG TTA GTG CTG GTA GCA GCC GCA TTT CCC GAA GGT GTA GG-3' and 5'-CC TAC ACC TTC GGG AAA TGC GGC TGC TAC CAG CAC TAA CTG-3' (mutated bases are underlined in the forward primer). The 481YIHR -> YIQQ mutation was made by amplifying the wild type construct using the primers 5'-G CTG CAA GAT TAC ATC CAG CAA GCA GGG AGA GTG GGC-3' and 5'-GCC CAC TCT CCC TGC TTG CTG GAT GTA ATC TTG CAG C-3', and the 286DEAD -> DQAD mutation was made with amplification of wild type construct using the primers 5'-G GTG TTG GAT CAG GCA GAC ACA CTG C-3' and 5'-G CAG TGT GTC TGC CTG ATC CAA CAC C-3'. A double mutant (DM1) was made by mutating the 286DEAD -> DQAD construct with the YIHR -> YIQQ primers. The suspected nuclear export signal (NES) sequence was mutated in two steps. Initially three leucines were mutated by amplification from the wild type MDDX28-EGFP-N1 using the primers 5'-CC CTC GTG ACT CGG GCG GCC GCG GCG CCG CGA CGG GGC-3' and 5'-GCC CCG TCG CGG CGC CGC GGC CGC CCG AGT CAC GAG GG-3'. This was further mutated to 9AFSAVTRAAA (NES-5) with primers 5'-G CGG CCG GTG CGG GCC TTT TCC GCC GTG ACT CGG GC-3' and 5'-GCC CGA GTC ACG GCG GAA AAG GCC CGC ACC GGC CGC-3'. Three basic regions corresponding to amino acids 49–58, 98–104, and 244–247 containing putative nuclear localization signals were mutated using the wild type or {Delta}520–540 constructs as templates and the following primers: NLS-1, 5'-CAG CGG CAG AGC GCG GCG GCG AAC CTC CCG AGG-3' and 5'-CCT CGG GAG GTT CGC CGC CGC GCT CTG CCG CTG-3'; NLS-2, 5'-GGC TGG AAG AGT GCA GCC GCG GCT CGG GAC CAC TTC-3' and 5'-GAA GTG GTC CCG AGC CGC GGC TGC ACT CTT CCA GCC-3'; and NLS-3, 5'-GGC CAC GGC ATG GCT GCG ATC GCC CTG CAG CTG TCC-3' and 5'-GGA CAG CTG CAG GGC GAT CGC AGC CAT GCC GTG GCC-3'. The various mutations were combined to give 14 different mutated constructs (Table I). {Delta}NLS constructs contain BamHI/EcoRI-digested fragments amplified with forward primer, 5'-GGAATTCAGCCACCATGCGGCAGTTGGAACAG-3', and reverse primer, 5'-GGTGGATCCGCGATGGAGAAGTGGTC-3', using wild type, NLS-1, NLS-2, or NLS-1/2 as templates.

The twenty N-terminal amino acids from MDDX28 were inserted into TCF11 (11) to give the constructs TCF/NES-R (right orientation of insert) and TCF/NES-W (wrong orientation of insert). The PshAI/EcoRV fragment of TCF11 was transferred to an EcoRV/PshAI-cleaved pUC19 vector (New England Biolabs). Two 63-bp oligonucleotides identical to the 5' end of the MDDX28 gene were synthesized on an Applied Biosystems model 394 DNA/RNA synthesizer. The oligonucleotides were complementary over 59 bp, with 4-bp 3' overhangs identical to the cohesive ends of an NcoI restriction site. The oligonucleotides were annealed, treated with T4 polynucleotide kinase (New England Biolabs), and ligated to an NcoI-cleaved pUC19-TCF11 construct in both directions. These constructs were then transferred to pcDNA3 by cleaving vector and insert with EcoRI and XbaI.

Cell Culture and Immunofluorescence—COS-1 cells were grown on coverslips in Dulbecco's modified Eagle's medium (BioWhittaker) supplemented with 10% newborn calf serum (BioWhittaker) and 2 mM L-glutamine (Invitrogen). At appropriate times, the coverslips were washed briefly in PBS and fixed in 4% paraformaldehyde (Ferak) for 15 min (except for anti-PSP-1, 7 min). The cells were permeabilized in 0.5% Triton X-100 in PBS and blocked for 30 min in 3% bovine serum albumin (Sigma) in PBS. The samples were incubated with the primary antibody in 1% blocking solution at 4 °C overnight, washed 3 times in PBS with 0.1% Triton X-100, and incubated for 1h at room temperature with fluorescence-conjugated secondary antibody. When appropriate, the cells were counterstained with Hoechst 33258 (Sigma) before mounting. The samples were viewed with a Nikon Eclipse E400 microscope. The pictures were taken at 100x primary magnification with a SPOT digital camera and combined with SPOT32 software (Diagnostic Instruments). Alternatively, confocal laser-scanning microscopy images were recorded on a TCS SP scanner mounted on a DM IRBE microscope (Leica Microsystems Heidelberg GmbH). The objective was a Plan Apo 63X/1.32 oil immersion lens. Laser (dual) excitation was done at 488 (or 476) and 546 nm; the main beam splitter was a dual band pass filter DD488/568. The fluorescence detection bands in the scanner head were set to optimize detection and minimize bleed-through. The pinhole was set to 1.00 absorbance units. The photodetectors were class R6357/R6358 photomultiplier tubes (Hamamatsu Photonics KK). Data acquisition and data analysis were controlled by means of the LCS software version 2.770 (Leica Microsystems Heidelberg GmbH). A series of 40 sections at an axial distance of 4.9 µm and with a strong zoom factor (7.5) was used as raw data for three-dimensional image reconstruction. A simulated fluorescence process shadow projection series (61 images at 3° rotational progression) was created from median-filtered raw data (kernel size 5 x 5 x 3) with the LCS software. The series was saved as an avi-file and compressed from 48 to 5.9 kilobytes with the AVIedit software.

Transfections into COS-1 cells were performed using the FuGENE 6 transfection reagent in 4:1 FuGENE/plasmid ratio according to the Roche Applied Science protocol. Heterokaryon assays were performed as described earlier (1), except that treatment with cycloheximide was shortened in the assay of the TCF/NES constructs because the TCF11 protein has a half-life of less than 3 h.2

For RNase and DNase treatment of transfected cells, a method of Chiodi et al. (12) was followed. Briefly, {Delta}2–20-transfected cells that had been treated with actinomycin D for 2 h were washed with cold PBS and incubated for 10 min in Buffer A (100 mM NaCl, 300 mM sucrose, 10 mM Pipes, pH 6.8, 3 mM MgCl2, and 0.1% Triton X-100) containing protease inhibitors (PIC, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml antipain, 10 µg/ml chymostatin, 10 µg/ml phosphoramidon, 1 mM phenylmethylsulfonyl fluoride). Cells were incubated for 10 min in the same buffer made to 250 mM in ammonium sulfate and washed twice in Buffer A before treatment for 20 min at 37 °C with 36 µg/ml of RNase A (Sigma) in Buffer A. Cells were then washed in PBS and fixed in ice-cold methanol.

Antibodies used were anti-SC35 (a generous gift of Dr. Kallan, University of Bergen), anti-p80 coilin (a generous gift of Dr. Lamond, University of Dundee), anti-paraspeckle protein-1 (PSP-1, a generous gift of Dr. Fox, University of Dundee), and Hsp60 (Stressgen Biotechnologies). For anti-promyelocytic leukemia bodies (PML), the monoclonal antibody 5E10 (13) was used. TCF/NES was detected with anti-nrf1 antibody (Santa Cruz Biotechnology). TRITC-, fluorescein isothiocyanate-, and Texas Red-conjugated secondary antibodies were used (DAKO, The Jackson Laboratories). All immunofluorescence studies were repeated at least twice, and all readings and quantifications were done blindly. Nucleolar, mitochondrial, and cytoplasmic localization were scored as present or not present, whereas nuclear localization was scored according to intensity of the localization as compared with the wild type.

Transcription Inhibition—Transiently transfected cells were grown for 20–24 h on coverslips before treatment with 10 µg/ml actinomycin D (Sigma). After 2 h (unless otherwise stated) the cells were fixed as described above and viewed immediately in the fluorescence microscope.

Immunoprecipitation—Transfected COS-1 cells were cultured in 10-cm tissue culture dishes. The constructs were tested for equal transfection efficiency with direct immunofluorescence. One day post-transfection, 40 µl of [14C]uridine (50 µCi/ml) was added to the cultures, and incubation was continued overnight. The cells were washed in PBS and incubated on ice in radioimmune precipitation assay buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing PIC. The cells were scraped off, homogenized, and centrifuged briefly at full speed in a bench-top centrifuge to remove debris. The extracts were precleared with 20 µl of M280 Dynabeads coated with sheep-anti-rabbit IgG (Dynal) for 1 h at 4 °C. Dynabeads were conjugated with 1.5 µg of GFP antibody (Santa Cruz Biotechnology) and incubated for 2 h at 4 °C. Conjugated beads were then added to precleared extracts and incubated at room temperature for 2 h. The beads were washed 3 times in PBS, suspended in 50 µl of PBS and mixed with Pico Aqua liquid scintillation mixture (Packard). The samples were counted in a Packard 1600TR liquid scintillation analyzer. The counting was adjusted for total protein of each sample as measured with the Bio-Rad assay. Background (EGFP-N1 vector only) was subtracted. The experiment was repeated three times.

Statistics—The distribution of the number of punctate structures containing SC35 and MDDX28 was compared in ~100 cells with a two-tailed independent sample t test using the SPSS software package.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Mitochondrial Targeting Signal (MTS)—Both endogenous MDDX28 and protein fused to EGFP are localized to the mitochondria of all cells, implying that it may be constantly needed in the organelle, e.g. in connection with the continuous mitochondrial transcription (1). We had previously predicted that a MTS was located at amino acids 3–18 of MDDX28 (1) because this sequence has the MTS characteristics consisting of 16 amino acids, potentially forming an amphiphilic {alpha}-helix with a net positive charge. To determine whether this was the MTS sequence, MDDX28 lacking the first 20 amino acids ({Delta}2–20) was cloned into the EGFP-N1 vector. When this construct was transfected into COS-1 cells the protein was no longer expressed in the mitochondria (see Fig. 2A), confirming that the first 20 amino acids of MDDX28 are necessary for the mitochondrial localization. To find out whether this sequence alone is sufficient for mitochondrial localization, a construct coding only for the first 44 amino acids of MDDX28 was made ({Delta}44–540), tagged with EGFP-N1, and transfected into COS-1 cells. The corresponding fusion protein had only mitochondrial localization (Fig. 2A), showing the sufficiency of the sequence for mitochondrial localization. Only after prolonged incubation of the transfected cells (48 h) did the {Delta}44–540 protein start to appear in the cytoplasm, possibly due to saturation of the mitochondrial import (data not shown).



View larger version (49K):
[in this window]
[in a new window]
 
FIG. 2.
Intracellular localization of recombinant proteins derived from various expression constructs. COS-1 cells were grown on coverslips and transfected with various constructs. The cells were washed in PBS, fixed with 4% paraformaldehyde, mounted, and viewed with Nikon Eclipse E400 microscope. Pictures were taken with a SPOT digital camera. Primary magnification, 100x. Representative cells are shown. A, mitochondrial localization of various expression constructs. Only the nucleus is seen in figures with TCF/NES-W and NES-5. {Delta}2–20 is in green, with the mitochondrially localized Hsp60 protein in red. {Delta}44–540 is in green, and to the right the same cell stained with Hsp60 antibody is shown in red. B, heterokaryon assay. Transport of the TCF/NES-R (a–c) and NES-5 (d–f) fusion proteins from the nuclei of transfected COS-1 cells to the nuclei of untransfected NIH/3T3 cells (arrows). The TCF11-containing fusion protein was detected with anti-nrf1 antibody (Santa Cruz Biotechnology (b)). The cells were counterstained with Hoechst 33258 (a and d) to distinguish the nuclei of COS-1 and NIH/3T3 cells. c and f are brightfield exposures. C, nuclear localization of recombinant proteins derived from various expression constructs. The graphs show nuclear localization of protein encoded by various constructs after treatment with actinomycin D (a) and nuclear localization of protein encoded by NLS mutants (b). The transfection was repeated three times. The counting was done blindly. As supplemental material, a videoclip showing a three-dimensional image reconstruction of an SFP-shadow projection series (61 images at 3° rotational progression) was created from median-filtered raw data (kernel size 5 x 5 x 3) with the LCS software. The raw data was a series of 40 sections through a cell transfected with the {Delta}{Delta}7 construct at an axial distance of 4.9 µm and with a strong zoom factor (7.5). The SFP-shadow projection series was saved as an avi-file and compressed from 48 to 5.9 kilobytes with the AVIedit software. D, nucleolar localization of recombinant proteins derived from various expression constructs. Wt, wild type.

 

Right orientation insertion of the 20 N-terminal amino acids of MDDX28 into the transcription factor TCF11 (TCF/NES-R, Fig. 1) was sufficient for mitochondrial localization of the otherwise nuclear-localized protein (Fig. 2A). The mitochondrial localization of this fusion protein is less visible in Fig. 2B, b, possibly due to the treatment with protein synthesis inhibitor. Wrong orientation of the insert (TCF/NES-W) did not result in mitochondrial localization (Fig. 2A). This shows that not only the sequence but also its correct orientation is necessary for mitochondrial transport.

NES—We have previously shown that when MDDX28-transfected cells are treated with actinomycin D the protein is effectively exported from the nucleus (1). The protein does not reappear in the nucleus during transcription inhibition, suggesting that its re-entry into the nucleus is blocked, e.g. by masking of the nuclear localization signal (NLSs) by binding proteins or by phosphorylation. To search for NES in MDDX28, the nuclear localization of proteins encoded by several single deletion constructs (Fig. 1) was assessed after 8–24 h of actinomycin D treatment. Whereas {Delta}149–274, {Delta}276–540, and {Delta}520–540 as well as the wild type protein were successfully exported from the nucleus, the {Delta}2–20 and {Delta}2–139 mutants remained in the nucleus of all cells even after 24 h of treatment (Fig 2C, graph a). We also noticed that, unlike the wild type protein, which localized to the nucleus in about half of the transfected cells, the {Delta}2–20 and {Delta}2–139 proteins as well as the {Delta}520–540 protein localized to the nucleus in all transfected cells.

To test whether amino acids 1–20 were sufficient to enable nuclear export, they were inserted in both directions into the N-terminal end of the short version of the nuclear-localized transcription factor TCF11 (TCF/NES-R and -W, Fig. 1). The nuclear export ability of the two constructs was examined in an interspecies heterokaryon assay. Untransfected NIH/3T3 mouse cells were fused to COS-1 cells that had been transfected with the TCF/NES constructs. The cells were treated with 50 µg/ml cycloheximide for 1 h before and for 1 h after the fusion before fixation with paraformaldehyde. Therefore, all fusion protein present in the nucleus of NIH/3T3 cells would have originated in the transfected COS-1 cells. To distinguish the nuclei derived from mouse and monkey cells, the cells were counterstained with Hoechst 33258 after fixation. The TCF/NES-R protein was seen in the nucleus of NIH/3T3 cells (Fig. 2B, a–c) in numerous heterokaryons on every coverslip examined, indicating that the inserted sequence was active as an export signal. Six coverslips were scanned in the heterokaryon assay for TCF/NES-W, and only one NIH/3T3 nucleus containing TCF11 was found (data not shown). Thus, TCF/NES-W was largely incapable of nucleocytoplasmic shuttling, indicating that NES in the wrong orientation was not active as an export signal.

A leucine-rich sequence is located at amino acids 9–18. To test whether the leucine residues were necessary for the nuclear export, all five were mutated to alanine (9LFSLVTRLLL -> AFSAVTRAAA, NES-5). After 24 h of actinomycin D treatment of cells transfected with NES-5, the protein was seen in the nucleus of 70% of cells transfected with the NES-5 construct compared with 10–20% for the wild type. Thus, although mutation of the five leucine residues impaired the nuclear export ability of the protein, it had not been completely inhibited. The export of the NES-5 mutant was further established using a heterokaryon assay (Fig. 2B, d–f). Together these results suggested that the leucine residues were important but not absolutely essential for nuclear export and that other residues among the 20 N-terminal amino acids are involved in the export. The mitochondrial localization of protein encoded by the NES-5 construct was also greatly decreased (Fig. 2A), indicating that residues that play a role in the nuclear export are also necessary for the mitochondrial import of MDDX28.

NLS—We had predicted earlier that the NLS might be the basic stretch of amino acids at positions 520–523 (RRRR), but deletion of these ({Delta}520–540) failed to impair the nuclear import of the fusion protein (Fig. 2C). To search for the NLS, three deletion constructs were made, together spanning the whole protein ({Delta}2–139, {Delta}149–274, and {Delta}276–540). The resulting proteins all localized to the nucleus (Fig. 2C), suggesting that the nuclear localization signal is a composite, where no single sequence is essential. At this stage, the possibility could not be ruled out that MDDX28 enters the nucleus through a piggyback mechanism. Such a mechanism has been suggested, e.g. for protein X of hepatitis B virus that is imported into the nucleus by binding to the NLS-carrying I{kappa}B{alpha} (14).

To distinguish between active nuclear import and a piggyback mechanism, we looked for candidate NLS in MDDX28. The most common type of NLS is made of one, two, or more mono- or bipartite stretches of basic amino acids (15). MDDX28 contains three basic stretches (BS 1–3), at amino acids 49–58, 98–104, and 244–247 in addition to the previously identified basic stretch at position 520–523 (BS-4). To test whether one or more of the basic regions were important for the nuclear import, 14 different combinations of mutated basic regions were made (Table I). No decrease in the number of cells with nuclear localization of the fusion protein or in the intensity of the localization was detected in cells transfected with NLS-3, {Delta}520–540, or a combination of the two (Fig. 2, C–D, and data not shown). However, mutation of BS-1 and 2 (NLS-1 and -2 constructs, respectively) significantly decreased the nuclear import of the corresponding protein, both seen as a decrease in the number of cells with nuclear localization (Fig. 2C, graph b) and in decreased intensity of immunofluorescence in the nucleus (Fig. 2D). Mutations of both BS-1 and -2 (NLS-1/2) decreased the nuclear localization further, to about 7% of transfected cells, indicating that the nuclear import was greatly impaired (Fig. 2C, graph b). Because the import was not completely inhibited by mutating the two basic regions, other NLS with very limited activity may be present in MDDX28. Alternatively, the mutations introduced into BS-1 and -2 may only partially impair the NLSs, leaving a small part of the signal intact. Deletion of the region around the two basic clusters ({Delta}2–139) did not exclude the resulting protein from the nucleus (Fig. 2C), indicating the presence of additional NLSs in the protein.

To test if additional amino acids surrounding BS-3 and -4 were important for the nuclear localization, we analyzed five deletion constructs, each covering at least two of the basic stretches ({Delta}{Delta}1, {Delta}{Delta}2, {Delta}{Delta}4, {Delta}{Delta}7, and {Delta}2–274). Only when all four basic stretches and the surrounding amino acids had been deleted ({Delta}{Delta}7) was the protein completely excluded from the nucleus (Fig. 2C). The absence of the {Delta}{Delta}7-encoded protein from the nucleus was further established with confocal microscopy. Seven single cells (or their nuclei) were examined. These revealed that no fluorescent particles matching GFP spectral properties were located inside the nucleus (an animation of the three-dimensional projection is available as Supplemental Material). This indicated that residues between 139 and 274 and C-terminal residues could also contribute to the nuclear localization.

To address the question of whether BS-1 and -2 were sufficient for nuclear localization, four constructs were made with amino acids 44–109 of MDDX28 (containing both clusters) fused to EGFP (Fig. 1). When the basic clusters were in the wild type form ({Delta}NLS) the fusion protein was primarily seen in the nucleus of the transfected cells (Fig. 2C). Mutation of either of the basic clusters ({Delta}NLS-1 and {Delta}NLS-2) resulted in protein that was localized to nucleus and cytoplasm, where the intensity of nuclear-localized protein was much higher than that of the cytoplasmic protein (Fig. 2C). The intracellular localization of a fusion protein where both clusters had been mutated ({Delta}NLS-1/2) could not be distinguished from the localization pattern of EGFP alone (Fig. 2C). This indicated that {Delta}NLS-1/2 had lost all localization information. Taken together, these results show that BS-1 and -2 are sufficient for nuclear localization and that mutation of either signal sequence reduced the efficiency of the NLS.

It has been proposed that actinomycin D "inactivates" NLS, thereby shifting the localization of nuclear-shuttling proteins to the cytoplasm (16). We tested whether the NLSs of MDDX28 were differently affected by inhibition of transcription. After 8–24 h of treatment, NLS-1- and NLS-2-transfected cells showed a greatly reduced presence of MDDX28 in the nucleus. This reduction was not significantly different from that observed for the wild type protein (data not shown). This indicated that actinomycin D could inactivate the two major NLSs of MDDX28.

Nucleolar Localization Signal (NoLS)—The wild type MDDX28 localized to the nucleolus in up to 20% of transfected cells, depending on time after transfection (1). To look for the NoLS, the nucleolar localization of three deletion constructs ({Delta}2–139, {Delta}149–274, and {Delta}276–540) spanning the whole protein was studied. All the constructs resulted in proteins that lacked nucleolar localization (Fig. 2C). Because the deletions of the constructs do not overlap, we suggest that the NoLS is composed of two or more sequences, which are all essential. Alternatively, the nucleolar localization depends on the enzymatic activity of the protein. Large parts of the conserved enzymatic domain had been deleted from the two constructs, the encoded fusion proteins of which no longer localized to the nucleolus.

We first addressed the question whether function of MDDX28 was important for the localization of the protein. Drawing on the experience with the eIF4A protein (17, 18), we mutated MDDX28 in three of the conserved motifs, 330GAT -> AAA (SAT in eIF4A), 286DEAD -> DQAD, and 481YIHR -> YIQQ. The corresponding residues in the eIF4A protein affected the helicase function, the ATP hydrolysis, and the RNA binding, respectively. Cells transfected with the DEAD and GAT mutants retained the nucleolar localization of the protein (Fig. 2D). Interestingly, the mutation of the DEAD-box resulted also in cytoplasmic but not mitochondrial localization (Fig 2D). Mutation of the YIHR motif completely inhibited the nucleolar localization of the fusion protein (Fig. 2D), suggesting its dependence on the RNA binding ability of the protein. Double-mutated MDDX28 (DM1, 286DEAD -> DQAD; 481YIHR -> YIQQ) had the same localization as 286DEAD -> DQAD, except that it did not localize to the nucleolus (Fig. 2D). To test whether the 481YIHR -> YIQQ mutation affected the RNA binding of MDDX28, the hybrid protein was immunoprecipitated from transiently transfected COS-1 cells that had been cultured overnight in the presence of [14C]uridine. The results were normalized to the total amount of protein in each precipitate, and the background (activity pulled down with EGFP-only) was subtracted. The 481YIHR -> YIQQ-mutated protein had significantly reduced RNA binding ability compared with the wild type protein or protein containing the 330GAT -> AAA mutation (Fig. 3A). The importance of interaction with RNA for the nucleolar localization of MDDX28 was further established by treating transfected, transcription-inhibited cells with RNase A for 20 min before fixation in methanol. This resulted in removal of nucleolar-localized MDDX28 protein in 50% of the cells, whereas treatment with Triton X-100 and ammonium sulfate, designed to remove nuclear proteins not interacting stably with either chromatin or the nuclear matrix, did not significantly affect the nucleolar localization (Fig. 3B). The localization pattern of MDDX28 in cells retaining nucleolar localization after RNase A-treated cells was also different from that of untreated cells (Fig. 3C). Only protein localized in the fibrillar center (FC) remained after the RNase A treatment (Fig. 3C, a), whereas protein localized to the dense fibrillar component and the granular component were removed by the treatment. This agrees with the findings that dense fibrillar component and granular component contain the ribonucleoprotein complexes, whereas the FCs are depots of rDNA genes (for a review, see Ref. 19).



View larger version (13K):
[in this window]
[in a new window]
 
FIG. 3.
RNA binding of MDDX28. A, RNA binding of recombinant proteins derived from various expression constructs detected by immunoprecipitation. Transfected COS-1 cells were incubated with 40 µl of [14C]uridine (50 µCi/ml) overnight. The fusion proteins were immunoprecipitated using anti-GFP antibody (Santa Cruz Biotechnology) bound to sheep-anti-rabbit IgG-coated M280 Dynabeads (Dynal) as described under "Experimental Procedures." B, dependence of nucleolar localization (loc.) of MDDX28 on RNA binding. Cells transfected with the {Delta}2–20 construct were treated with actinomycin D for 2 h, washed with cold PBS, and incubated for 10 min in Buffer A that contains 0.1% Triton X-100. Cells were incubated for 10 min in the same buffer made to 250 mM ammonium sulfate (Amm.Sulf.) and washed twice in Buffer A before treatment for 20 min at 37 °C with 36 µg/ml of RNase A (Sigma) in Buffer A. Cells were then washed in PBS and fixed in ice-cold methanol. The experiment was repeated twice. The samples were counted blindly for nucleolar localization of MDDX28. C, nucleolar localization of MDDX28 in RNase A-treated (a) and control sample (b). Wt, wild type.

 

Thus, we have shown that the nucleolar localization of MDDX28 depends on the RNA binding of the YIHR motif at amino acids 481–484. However, because proteins encoded by the {Delta}2–139 and {Delta}149–274 constructs did not localize to the nucleolus although these deletions leave the YIHR box intact, other parts of the protein must also contribute to its nucleolar localization. Because the most common NoLS identified to date consists of a cluster of basic amino acids (20, 21) we tested whether mutations of basic regions BS 1–4 could affect the nucleolar localization. Protein encoded by the NLS-1, NLS-2, and NLS-3 constructs were all excluded from the nucleolus in transiently transfected cells (Fig. 2D), suggesting that in addition to the RNA binding ability, the basic regions of the protein are necessary for its nucleolar localization.

Transcription Inhibition-dependent Nuclear Localization— We have reported earlier that the nuclear localization of MDDX28 depends on ongoing polymerase II transcription (1). When testing the effect of RNA polymerase II inhibition on the nuclear localization of protein encoded by the MDDX28 constructs we also noticed marked changes in the nuclear phenotype of cells transfected with the {Delta}2–20, {Delta}520–540, or the wild type construct as well as of the endogenous MDDX28. Shortly after the addition of actinomycin D, these proteins were seen in punctate structures in the nucleoplasm and in caps at the nucleolar periphery (Fig. 4A, a, d, and g; data not shown for {Delta}520–540, the wild type construct or endogenous protein). The same effect was obtained with other polymerase II inhibitors ({alpha}-amanitin and 5,6-dichloro-1-{beta}-D-ribofuranosylbenzimidazole; data not shown). This suggests that the protein accumulates in subcompartments of the nucleus during transcription inhibition. The protein disappeared from the punctate structures after 4 h of actinomycin D treatment in cells transfected with the wild type and {Delta}520–540 constructs as a result of the protein being exported from the nucleus (data not shown). Therefore, this phenomenon was not observed in the previous study where the shortest time studied was 4 h post-initiation of actinomycin D treatment (1). The {Delta}2–20 protein has lost the NES and is, therefore, not exported from the nucleus. Accordingly, it was still localized in the punctate structures after 24 h of actinomycin D treatment. Interestingly, localization to the punctate structures during transcription inhibition was not observed in cells transfected with constructs not encoding protein localized to the nucleolus, including the YIHR mutant and the NLS-1, NLS-2, and NLS-3 mutants (data not shown).



View larger version (40K):
[in this window]
[in a new window]
 
FIG. 4.
Co-localization of MDDX28 punctate nuclear structures with known nuclear bodies. COS-1 cells were grown on coverslips and transfected with {Delta}2–20. One day post-transfection, 10 µg/ml actinomycin D was added to the cultures for 2 h. A, the cells were fixed and stained with PML (b), SC35 (e), p80-coilin (h), and PSP-1 (k). c, f, i, and l are merged pictures showing the co-localization. Primary magnification, 100x. Only the nuclei are shown. B, transcription inhibited {Delta}2–20-transfected cells (green) stained with SC35 (a–e) (red) and p80-coilin (f–j) (red) were viewed with confocal laser microscopy. Red and green images were merged. Five consecutive focal planes of the same cells are shown, with 0.2-µm step size. Primary magnification, 63x. Only the nuclei are shown. Arrows indicate adjacent localization.

 

We have studied whether MDDX28 in punctate nuclear structures colocalizes with other known nuclear bodies (PML bodies, splicing speckles, Cajal bodies (coiled bodies), and paraspeckles) by staining actinomycin D-treated cells with antibodies against PML (Fig. 4A, b), SC35 (Fig. 4A, e), p80-coilin (Fig. 4A, h), and PSP-1 (Fig. 4A, k). Only the results for {Delta}2–20 are shown, because its localization to the punctate structures is not affected by nuclear export, and therefore, the intensity of the structures remains stronger. The same results were obtained for the wild type protein (data not shown). The punctate nucleoplasmic structures did not co-localize with PML, p80-coilin, or PSP-1; however, they were found to be adjacent to (but did not colocalize with) the SC35 protein detected in conventional immunofluorescence studies (Fig. 4A, f). This was further confirmed with confocal microscopy (Fig. 4B, a–e). SC35 speckles are bigger than the punctate structures containing MDDX28. However, the number of these two structures in transcription-arrested cells did not show significantly different distribution (p > 0.422, Fig. 5).



View larger version (11K):
[in this window]
[in a new window]
 
FIG. 5.
Number of punctate nuclear structures. COS-1 cells were grown on coverslips and transfected with {Delta}2–20. One day post-transfection, 10 µg/ml actinomycin D was added to the cultures for 2 h. The cells were fixed and stained with SC35 antibody. The number of MDDX28- and SC35-containing speckles were counted and compared in a two-tailed t test with SPSS software package.

 

MDDX28 also formed caps at the nucleolar periphery in cells treated with actinomycin D. These were found to partially co-localize with PSP-1 (Fig. 4A, l) and to be adjacent to p80-coilin (Fig. 4A, i), as observed with conventional immunofluorescence microscopy. The adjacent colocalization with p80-coilin was further confirmed with confocal microscopy (Fig. 4B, f–j).


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The subcellular localization of the MDDX28 protein is novel for RNA helicases. MDDX28 is a nuclear shuttling protein also found in the nuclear subcompartments and in the mitochondria. We have studied the signals that direct the protein to these various localizations.

Most mitochondrial proteins are encoded in the nucleus, synthesized in the cytoplasm, and transported into the mitochondria either post- or co-translationally (for a review, see Ref. 22). No consensus sequence has been found for mitochondrial localization; however, sequences with shared characteristics have been described (23). The first 20 amino acids of MDDX28 have such MTS characteristics, and these were found to be both necessary and sufficient for mitochondrial localization of the protein in deletion and domain-swapping experiments. The EGFP protein and the transcription factor TCF11 gained mitochondrial localization when fused to the MTS sequence of MDDX28, whereas full-length MDDX28 lacking only the MTS did not localize to the mitochondria. The orientation of the sequence was found to be important, because only MTS inserted in the right orientation resulted in mitochondrial localization of the otherwise nuclear-localized TCF11. Furthermore, the five leucine residues of the sequence were essential for the mitochondrial localization.

A mutation of the conserved DEAD-box (286DEAD -> DQAD) resulted in protein localized to the nucleus and to the cytoplasm but not to the mitochondria. Due to the cytoplasmic localization of the 286DEAD-mutated protein it was not possible to test the shuttling ability of the protein in a heterokaryon assay. The DEAD-box is a Walker B motif involved in ATP hydrolysis and is highly conserved among RNA helicases. The 286DEAD -> DQAD mutation has been shown to affect the ATP hydrolysis and not ATP binding to RNA helicases (17, 24). Furthermore, it has been shown that ATP hydrolysis causes conformational changes of the eIF4A helicase and decreases its affinity for single-stranded RNA 40-fold (25). Based on the similarity of the core domain of eIF4A and MDDX28 and the finding that a double-mutated MDDX28 (DM1, 286DEAD -> DQAD; 481YIHR -> YIQQ) has the same localization as 286DEAD -> DQAD, we propose that in addition to the MTS, the conformational change caused by ATP hydrolysis is necessary for successful mitochondrial localization of MDDX28. This change of conformation may not be needed for {Delta}44–540, where nearly the whole MDDX28 is deleted. Transport of another RNA helicase, An3, is significantly affected by mutation of the DEAD motif (An3 E389Q; Ref. 26), indicating that similar mechanism may apply to the transport of both proteins.

In addition to functioning as a MTS, the first 20 amino acids of MDDX28 were found to be necessary and sufficient for nuclear export of the protein in deletion- and domain-swapping experiments. Transcription factor TCF11 was exported from the nucleus when fused to the NES sequence of MDDX28, whereas full-length MDDX28 lacking only the NES sequence was not exported from the nucleus. NES in the right orientation was much more efficient for nuclear export than NES in the wrong orientation.

Leucine-rich NES is the best-studied type of nuclear export signal (for a review, see Ref. 27). Proteins with leucine-rich NES as well as with NES rich in other hydrophobic amino acids are exported via the CRM1 pathway, which is sensitive to leptomycin B (27, 28, 29, 30). We have shown earlier that leptomycin B does not significantly alter the nuclear localization of MDDX28 (1), suggesting that the protein does not contain a classical leucine-rich NES. The 20 N-terminal amino acids of MDDX28 include 5 leucine residues. Although mutation of the leucine residues to alanine decreased the nuclear export of the resulting protein, it was not completely inhibited. This suggests that residues other than the N-terminal leucines of MDDX28 are also important for the nuclear export. Furthermore, the result presented here shows that the MTS and NES depend at least in part on the same amino acids within the sequence. Co-localization of these two signals has to our knowledge not been described before.

Most nuclear-localized proteins have been shown to rely on signal-mediated import (31). Therefore, we expect MDDX28 to contain a NLS for active nuclear import. This is further supported by the findings that MDDX28 is localized to the nucleus in about 50% of the cells, whereas it would be expected to localize to the nucleus of all cells if its nuclear import was passive. This further suggests that the protein is only temporarily needed in the nucleus or as a nucleo-cytoplasmic shuttling protein and that there is a mechanism for controlling its nuclear localization.

The most common NLS sequence is a small cluster of basic amino acids. Other types of NLS include the M9 sequence (38 amino acids long), which also mediates nuclear export, and the bipartite NLS, made of two small clusters of basic amino acids separated by 9–12 residues, (31) or NLS made of two or more mono- or bipartite basic domains separated by up to hundreds of amino acids (15, 32). We found that two clusters of basic amino acids, separated by 44 residues were necessary and sufficient for full nuclear localization of the protein in mutation and domain-swapping experiments. Additional unidentified NLS was also shown to contribute to the nuclear localization. Partial nuclear import was obtained with a series of deletion constructs where one or more basic clusters had been deleted or mutated. This is in concordance with the findings for proteins with two independent NLS, where both signals need to be deleted to fully inhibit the nuclear import (15, 33, 34).

Surprisingly, whereas protein encoded by {Delta}{Delta}7 is cytoplasmic, {Delta}NLS-1/2-encoded protein is diffusely localized in nucleus and cytoplasm. Both constructs contain EGFP fused to parts of MDDX28 lacking functional NLSs. This discrepancy can only be explained with the size difference between the two constructs. Together with EGFP, the size of the protein encoded by {Delta}{Delta}7 is ~54 kDa, whereas the size of the {Delta}NLS-1/2 protein is 35 kDa, apparently allowing passive nuclear import of the protein in the absence of intracellular targeting signal.

Little is known about the signal(s) that directs proteins to the nucleolus, although several proteins have been described with NoLS consisting of clusters of basic amino acids (20, 21). Even less is known about the mechanisms by which proteins are routed to the nucleolus, and no nucleolar transport proteins have yet been identified. It has been suggested that domains that are necessary and sufficient for nucleolar localization act as retention signals rather than targeting signals (35). MDDX28 was not identified as a nucleolar protein in a recent proteomic analysis of the nucleolus (36). We have shown, however, that the protein localizes to the nucleolus in a part of the cells, suggesting that the protein cycles between the nucleolus and other parts of the nucleus (1). We now show that the ability of MDDX28 to bind RNA is essential for the nucleolar localization of the protein, because mutation of the conserved YIHR motif completely inhibited the nucleolar localization as well as impaired the RNA binding ability of the protein. Furthermore, RNase A treatment of transfected cells significantly decreased the nucleolar localized protein.

In addition to the RNA binding ability, the three clusters of basic residues that are found in the N-terminal half of MDDX28 (BS 1–3) were shown to be independently necessary for the nucleolar localization. Two of these domains also confer nuclear localization of the protein, indicating that they are responsible not only for bringing the protein into the nucleus but also to the sites of RNA binding. The basic regions are hydrophilic and likely to be on the surface of the protein. They are, thus, possible sites of interaction of MDDX28 with other proteins or protein complexes, suggesting that both RNA and protein binding are needed for nucleolar targeting or retention of the protein in the nucleolus. Identification of proteins or protein-RNA complexes interacting with the basic regions of MDDX8 may reveal the function of the protein.

The nuclear localization of wild type MDDX28 is diffuse in untreated cells. When transcription inhibitors are added for 2 h, the protein relocates to punctate nucleoplasmic structures and to caps at the nucleolar periphery. We have found that only those MDDX28 constructs whose protein can localize to the nucleolus have the capability to form these structures, suggesting that the processes depend on the same mechanisms. This may be a combination of RNA and protein interactions. MDDX28 in punctate nucleoplasmic structures were adjacent to the splicing factor SC35, which upon transcription inhibition relocates to interchromatin granule clusters (37), normally associated with transcription of highly active genes (for a review, see Ref. 38). The organization of the nucleolus itself changes upon transcription inhibition; the compartments of the nucleolus disperse, and a necklace of tandemly organized rDNA and transcription of rRNA forms at the nucleolar periphery (39). After transcription, inhibition MDDX28 localized to the parts of the nucleolus that correspond to the necklace. There it partially co-localized with PSP-1 and was adjacent to p80-coilin, both of which have earlier been shown to relocate to nucleolar caps upon inhibition of transcription (40). The function of these proteins in the nucleolar caps is not yet known, and it remains to be resolved whether they are functionally related. At present the co-localization study serves only to identify the subnuclear compartments in which MDDX28 is trapped upon transcription inhibition. We have not studied whether MDDX28 interacts directly with the proteins with which it was shown to colocalize, and no other MDDX28-interacting proteins have yet been identified.

In conclusion, we have mapped the intracellular targeting signals of the MDDX28 protein. The conservation of signals for dual or triple purposes is interesting in terms of evolution as well as in understanding the control and function of MDDX28.


    FOOTNOTES
 
* This work was supported by grants from the Research Council of Norway, the Norwegian Cancer Society, and the Jahre Foundation (to H. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

The on-line version of this article (available at http://www.jbc.org) contains a video. Back

{ddagger} A Research Fellow of the Norwegian Cancer Society. Back

§ To whom correspondence should be addressed. Tel.: 47-22840532; Fax: 47-22840501; E-mail: hans.prydz{at}biotek.uio.no.

1 The abbreviations used are: EGFP, enhanced green fluorescence protein; BS, basic stretch; FC, fibrillar centre; MTS, mitochondrial targeting signal; NES, nuclear export signal; NLS, nuclear localization signal; NoLS, nucleolar localization signal; PML bodies, promyelocytic leukaemia bodies; PIC, protease inhibitor cocktail; PBS, phosphate buffered saline; PSP-1, paraspeckle protein-1; TRITC, tetramethylrhodamine isothiocyanate; Pipes, 1,4-piperazinediethanesulfonic acid. Back

2 C. Husberg, personal communication. Back


    ACKNOWLEDGMENTS
 
We are grateful to Dr. Eshrat Babaie for synthesis of all primers and oligonucleotides, Henning Johansen for sequencing all constructs, professor Anne-Brit Kolstø and Dr. Cathrine Husberg for advice and help with the TCF11 experiments, and Dr. Johannes Helm for excellent help with confocal microscopy.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Valgardsdottir, R., Brede, G., Eide, L. G., Frengen, E., and Prydz, H. (2001) J. Biol. Chem. 276, 32056-32063[Abstract/Free Full Text]
  2. Shibata, K., Itoh, M., Aizawa, K., Nagaoka, S., Sasaki, N., Carninci, P., Konno, H., Akiyama, J., Nishi, K., Kitsunai, T., Tashiro, H., Itoh, M., Sumi, N., Ishii, Y., Nakamura, S., Hazama, M., Nishine, T., Harada, A., Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K., Fujiwake, S., Inoue, K., and Togawa, Y. (2000) Genome Res. 10, 1757-1771[Abstract/Free Full Text]
  3. Jankowsky, E., Gross, C. H., Shuman, S., and Pyle, A. M. (2001) Science 291, 121-125[Abstract/Free Full Text]
  4. Mohr, S., Stryker, J. M., and Lambowitz, A. M. (2002) Cell 109, 769-779[Medline] [Order article via Infotrieve]
  5. Bird, L. E., Subramanya, H. S., and Wigley, D. B. (1998) Curr. Opin. Struct. Biol. 8, 14-18[CrossRef][Medline] [Order article via Infotrieve]
  6. Slusher, L. B., Gillman, E. C., Martin, N. C., and Hopper, A. K. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9789-9793[Abstract]
  7. Otterlei, M., Haug, T., Nagelhus, T. A., Slupphaug, G., Lindmo, T., and Krokan, H. (1998) Nucleic Acids Res. 26, 4611-4617[Abstract/Free Full Text]
  8. Willer, M., Rainey, M., Pullen, T., and Stirling, C. J. (1999) Curr. Biol. 9, 1085-1094[CrossRef][Medline] [Order article via Infotrieve]
  9. Lakshimpathy, U., and Campbell, C. (1999) Mol. Cell. Biol. 19, 3869-3876[Abstract/Free Full Text]
  10. Wang, Y., Lyu, Y. L., and Wang, J. C. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 12114-12119[Abstract/Free Full Text]
  11. Husberg, C., Murphy, P., Martin, E., and Kolstø, A.-B. (2001) J. Biol. Chem. 276, 17641-17652[Abstract/Free Full Text]
  12. Chiodi, I., Biggiogera, M., Denegri, M., Corioni, M., Weighardt, F., Cobianchi, F., Riva, S., and Biamonti, G. (2000) J. Cell Sci. 113, 4043-4053[Abstract/Free Full Text]
  13. Stuurman, N., de Graaf, A., Floore, A., Josso, A., Humbel, B., de Jong, L., and van Driel, R. (1992) J. Cell Sci. 101, 773-784[Abstract]
  14. Weil, R., Sirma, H., Giannini, C., Kremsdorf D., Bessia, C., Dargemont, C., Brechot, C., and Israel, A. (1999) Mol. Cell. Biol. 19, 6345-6354[Abstract/Free Full Text]
  15. Sudbeck, P., and Scherer, G. (1997) J. Biol. Chem. 272, 27848-27852[Abstract/Free Full Text]
  16. Henderson, B. R., and Eleftheriou, A. (2000) Exp. Cell Res. 256, 213-224[CrossRef][Medline] [Order article via Infotrieve]
  17. Pause, A., and Sonenberg, N. (1992) EMBO J. 11, 2643-2654[Abstract]
  18. Pause, A., Methot, N., and Sonenberg, N. (1993) Mol. Cell. Biol. 13, 6789-6798[Abstract]
  19. Carmo-Fonseca, M., Mendes-Soares, L., and Campos, I. (2000) Nat. Cell Biol. 2, 107-112
  20. Shu-Nu, C., Lin, C.-H., and Lin, A. (2000) FEBS Lett. 484, 22-28[CrossRef][Medline] [Order article via Infotrieve]
  21. Scott, M., Boisvert, F.-M., Vieyra, D., Johnston, R. N., Bazett-Jones, D. P., and Riabowol, K. (2001) Nucleic Acids Res. 29, 2052-2058[Abstract/Free Full Text]
  22. Lithgow, T. (2000) FEBS Lett. 476, 22-26[CrossRef][Medline] [Order article via Infotrieve]
  23. Omura, T. (1998) J. Biochem. (Tokyo) 123, 1010-1016[Abstract]
  24. Schmitt, C., von Kobbe, C., Bachi, A., Pante, N., Rodrigues, J. P., Boscheron, C., Rigaut, G., Wilm, M., Seraphin, B., Carmo-Fonseca, M., and Izaurralde, E. (1999) EMBO J. 18, 4332-4347[Abstract/Free Full Text]
  25. Lorsch, J. R., and Herschlag, D. (1998) Biochemistry 37, 2194-2206[CrossRef][Medline] [Order article via Infotrieve]
  26. Askjaer, P., Rosendahl, R., and Kjems, J. (2000) J. Biol. Chem. 275, 11561-11568[Abstract/Free Full Text]
  27. Ossareh-Nazari, B., Gwidzek, C., and Dargemont, C. (2001) Traffic 2, 684-689[CrossRef][Medline] [Order article via Infotrieve]
  28. Wolff, B., Sanglier, J. J., and Wang, Y. (1997) Chem. Biol. (Lond.) 4, 139-147[Medline] [Order article via Infotrieve]
  29. Fornerod, M., Ohno, M., Yoshida, M., and Mattaj, I. W. (1997) Cell 90, 1051-1060[Medline] [Order article via Infotrieve]
  30. Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M., and Nishida, E. (1997) Nature 390, 308-311[CrossRef][Medline] [Order article via Infotrieve]
  31. Christophe, D., Christophe-Hobertus, C., and Pichon, B. (2000) Cell. Signal. 12, 337-341[CrossRef][Medline] [Order article via Infotrieve]
  32. Chestukhin, A., Litovchick, L., Rudich, K., and De Caprio, J. A. (2002) Mol. Cell. Biol. 22, 453-468[Abstract/Free Full Text]
  33. Hall, M. N., Craik, C., and Hiraoka, Y. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 6954-6958[Abstract]
  34. Vandromme, M., Cavadore, J. C., Bonnieu, A., Froeschle, A., Lamb, N., and Fernandez, A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4646-4650[Abstract]
  35. Carmo-Fonseca, M. (2002) Cell 108, 513-521[Medline] [Order article via Infotrieve]
  36. Andersen, J. S., Lyon, C. E., Fox, A. H., Leung, A. K. L., Lam, Y. W., Steen, H., Mann, M., and Lamond, A. I. (2002) Curr. Biol. 12, 1-11[CrossRef][Medline] [Order article via Infotrieve]
  37. Hock, R., Wilde, F., Scheer, U., and Bustin, M. (1998) EMBO J. 17, 6992-7001[Abstract/Free Full Text]
  38. Mintz, P. J., Patterson, S. D., Neuwald, A. F., Spahr, C. S., and Spector, D. L. (1999) EMBO J. 18, 4308-4320[Abstract/Free Full Text]
  39. Panse, L. S., Masson, C., Hèliot, L., Chassery, J.-M., Junera, H. R., and Hernandez-Verdun, D. (1999) J. Cell Sci. 112, 2145-2154[Abstract/Free Full Text]
  40. Fox, A. H., Lam, Y. W., Leung, A. K. L., Lyon, C. E., Andersen, J., Mann, M., and Lamond, A. I. (2002) Curr. Biol. 12, 13-25[CrossRef][Medline] [Order article via Infotrieve]




This Article
Abstract
Full Text (PDF)
Data Supplement
All Versions of this Article:
278/23/21146    most recent
M300888200v1
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Copyright Permissions
Google Scholar
Articles by Valgardsdottir, R.
Articles by Prydz, H.
Articles citing this Article
PubMed
PubMed Citation
Articles by Valgardsdottir, R.
Articles by Prydz, H.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   Biochemistry and Molecular Biology Education 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.